# GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

> **NCT00157573** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 72 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** GM-CSF, sargramostim

## Key facts

- **NCT ID:** NCT00157573
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2008-10
- **Final completion:** 2010-04
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00157573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00157573, "GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00157573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*